Vanguard Global Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.87M Sell
7,682
-126
-2% -$66.6K ﹤0.01% 890
2026
Q2
$4.19M Sell
7,808
-239
-3% -$122K ﹤0.01% 862
2026
Q1
$4.21M Buy
+8,047
New +$3.84M ﹤0.01% 823

Other funds holding MDGL

Vanguard Global Advisers's MDGL Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Madrigal Pharmaceuticals (MDGL) stake by 1.6% in Q3 2026, selling an estimated $66.6K and leaving 7,682 shares worth $3.87M. The position accounts for ﹤0.01% of the portfolio, ranked #890.

Vanguard Global Advisers first reported a position in MDGL in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.21M in Q1 2026. 434 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Vanguard Global Advisers held 7,682 shares of Madrigal Pharmaceuticals worth $3.87M as of Q3 2026.
  • Vanguard Global Advisers sold 126 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $66.6K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #890 holding.
  • Vanguard Global Advisers first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Madrigal Pharmaceuticals position peaked at $4.21M in Q1 2026.
  • 434 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.